These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28299881)

  • 1. The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.
    Guinn D; Lehman A; Fabian C; Yu L; Maddocks K; Andritsos LA; Jones JA; Flynn JM; Jaglowski SM; Woyach JA; Byrd JC; Johnson AJ
    Cancer Med; 2017 Apr; 6(4):778-787. PubMed ID: 28299881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.
    Saleh LM; Wang W; Herman SE; Saba NS; Anastas V; Barber E; Corrigan-Cummins M; Farooqui M; Sun C; Sarasua SM; Zhao Z; Abousamra NK; Elbaz O; Abdelghaffar HA; Wiestner A; Calvo KR
    Leukemia; 2017 Feb; 31(2):340-349. PubMed ID: 27431016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
    Sharma S; Pavlasova GM; Seda V; Cerna KA; Vojackova E; Filip D; Ondrisova L; Sandova V; Kostalova L; Zeni PF; Borsky M; Oppelt J; Liskova K; Kren L; Janikova A; Pospisilova S; Fernandes SM; Shehata M; Rassenti LZ; Jaeger U; Doubek M; Davids MS; Brown JR; Mayer J; Kipps TJ; Mraz M
    Blood; 2021 May; 137(18):2481-2494. PubMed ID: 33171493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-34a and miR-29b as indicators for prognosis of treatment-free survival of chronic lymphocytic leukemia patients in Chinese Uygur and Han populations.
    Li Y; Mao M; Liu H; Wang X; Kou Z; Nie Y; Wang Y; Wang Z; Huang Q; Lang T; Gu Z; An L; Zhang X; Fu L
    Mol Cell Probes; 2019 Oct; 47():101436. PubMed ID: 31425738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
    Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
    Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. microRNA-126 inhibits tube formation of HUVECs by interacting with EGFL7 and down-regulating PI3K/AKT signaling pathway.
    Li Q; Cheng K; Wang AY; Xu QG; Fu ZF; He SY; Xu PX
    Biomed Pharmacother; 2019 Aug; 116():109007. PubMed ID: 31170663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells.
    Rozovski U; Calin GA; Setoyama T; D'Abundo L; Harris DM; Li P; Liu Z; Grgurevic S; Ferrajoli A; Faderl S; Burger JA; O'Brien S; Wierda WG; Keating MJ; Estrov Z
    Mol Cancer; 2013 Jun; 12():50. PubMed ID: 23725032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia.
    Yang YQ; Tian T; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Wang L; Fan L; Li JY; Xu W
    BMC Cancer; 2018 Oct; 18(1):1009. PubMed ID: 30348117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
    Jain P; Thompson PA; Keating M; Estrov Z; Ferrajoli A; Jain N; Kantarjian H; Burger JA; O'Brien S; Wierda WG
    Cancer; 2017 Jun; 123(12):2268-2273. PubMed ID: 28171709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
    Pekarsky Y; Santanam U; Cimmino A; Palamarchuk A; Efanov A; Maximov V; Volinia S; Alder H; Liu CG; Rassenti L; Calin GA; Hagan JP; Kipps T; Croce CM
    Cancer Res; 2006 Dec; 66(24):11590-3. PubMed ID: 17178851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
    Palma M; Krstic A; Peña Perez L; Berglöf A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Höglund P; Kimby E; Österborg A; Månsson R; Smith CIE
    Br J Haematol; 2018 Oct; 183(2):212-224. PubMed ID: 30125946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
    Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
    Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
    Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
    Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-4 Up-Regulates MiR-21 and the MiRNAs Hosted in the CLCN5 Gene in Chronic Lymphocytic Leukemia.
    Ruiz-Lafuente N; Alcaraz-García MJ; Sebastián-Ruiz S; García-Serna AM; Gómez-Espuch J; Moraleda JM; Minguela A; García-Alonso AM; Parrado A
    PLoS One; 2015; 10(4):e0124936. PubMed ID: 25909590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome.
    Albi E; Baldoni S; Aureli P; Dorillo E; Del Papa B; Ascani S; Di Ianni M; Falzetti F; Sportoletti P
    Tumori; 2017 Nov; 103(Suppl. 1):e37-e40. PubMed ID: 28708231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
    Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
    Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.